Table 2.
Propensity score matching and comparison in 30 patients who underwent surgery after neoadjuvant concurrent chemoradiotherapy.
| Characteristics | Previous cohort [7] (n=60) | mHealth group (n=30)a | P value | ||||||
| Age (years), median (SD) | 58.5 (7.8) | 59.2 (6.5) | .8 | ||||||
| Age group, n (%) |
|
|
.99 | ||||||
|
|
<60 years | 34 (56.7) | 17 (56.7) |
|
|||||
|
|
≥60 years | 26 (43.3) | 13 (43.3) |
|
|||||
| Smoking status, n (%) |
|
|
.41 | ||||||
|
|
Current smoker | 35 (58.3) | 14 (46.7) |
|
|||||
|
|
Ex- or nonsmoker | 25 (41.7) | 16 (53.3) |
|
|||||
| Tumor location, n (%) |
|
|
.73 | ||||||
|
|
Upper | 12 (20) | 4 (13.3) |
|
|||||
|
|
Middle | 21 (35) | 11 (36.7) |
|
|||||
|
|
Lower | 27 (45) | 15 (50) |
|
|||||
| cT stageb, n (%) |
|
|
.49 | ||||||
|
|
1-2 | 24 (40) | 9 (30) |
|
|||||
|
|
3-4 | 36 (60) | 21 (70) |
|
|||||
| cN stagec, n (%) |
|
|
.94 | ||||||
|
|
0-1 | 34 (56.7) | 18 (60) |
|
|||||
|
|
2-3 | 26 (43.3) | 12 (40) |
|
|||||
| Pre-RTd BMI (kg/m2), mean (SD) | 22.9 (2.8) | 22.9 (2.3) | .99 | ||||||
| Pre-RT BMI (kg/m2) |
|
|
.99 | ||||||
|
|
<20, n (%) | 7 (11.7) | 3 (10) |
|
|||||
|
|
≥20, n (%) | 53 (88.3) | 27 (90) |
|
|||||
| Post-RT BMI (kg/m2), mean (SD) | 22 (6) | 21.8 (2.6) | .65 | ||||||
| Post-RT BMI (kg/m2) |
|
|
|
||||||
|
|
<20, n (%) | 10 (16.7) | 7 (23.3) | .63 | |||||
|
|
≥20, n (%) | 50 (83.3) | 23 (76.7) |
|
|||||
| ∆BMI (kg/m2), mean (SD) | -0.8 (1.4) | -1.1 (1.2) | .38 | ||||||
| Pre-RT SMIe (cm2/m2), mean (SD) | 51.0 (9.1) | 51.3 (6.2) | .87 | ||||||
| Pre-RT SMI (cm2/m2) |
|
|
.99 | ||||||
|
|
Sarcopenia, n (%) | 36 (60) | 18 (60) |
|
|||||
|
|
Nonsarcopenia, n (%) | 24 (40) | 12 (40) |
|
|||||
| Post-RT SMI (cm2/m2), mean (SD) | 45 (7.8) | 45.9 (6.9) | .58 | ||||||
| Post-RT SMI (cm2/m2) |
|
|
.93 | ||||||
|
|
Sarcopenia, n (%) | 48 (80) | 23 (76.7) |
|
|||||
|
|
Nonsarcopenia, n (%) | 12 (20) | 7 (23.3) |
|
|||||
| ΔSMI (/50 days), mean, % (SD) | –8.1 (5.3) | –7.4 (6.5) | .57 | ||||||
| ΔSMI (/50 days) |
|
|
.94 | ||||||
|
|
Decreased >10%, n (%) | 20 (33.3) | 9 (30) |
|
|||||
|
|
Decreased <10%, n (%) | 40 (66.7) | 21 (70) |
|
|||||
| Laboratory markers |
|
|
|
||||||
|
|
WBCf(×103/μL), mean (SD) |
|
|||||||
|
|
|
Pre-RT | 8.2 (2.5) | 7.1 (1.7) | .02 | ||||
|
|
|
Post-RT | 4.8 (2.2) | 4.7 (2.8) | .93 | ||||
|
|
|
Δ | –3.4 (3.5) | -2.3 (2.8) | .05 | ||||
|
|
ANCg(×103/μL), mean (SD) |
|
|||||||
|
|
|
Pre-RT | 5.1 (2.2) | 4.4 (1.3) | .2 | ||||
|
|
|
Post-RT | 2.8 (2) | 2.6 (1.6) | .6 | ||||
|
|
|
Δ | –2.4 (3.1) | –1.8 (2.1) | .34 | ||||
|
|
ALCh(×103/μL), mean (SD) |
|
|||||||
|
|
|
Pre-RT | 2.2 (0.5) | 1.9 (0.6) | .02 | ||||
|
|
|
Post-RT | 1.3 (0.6) | 1.5 (1.3) | .6 | ||||
|
|
|
Δ | –0.9 (0.7) | –0.4 (1.3) | .11 | ||||
|
|
Platelet(×103/μL), mean (SD) |
|
|||||||
|
|
|
Pre-RT | 263.0 (72.2) | 260.3 (52.9) | .86 | ||||
|
|
|
Post-RT | 215.0 (70.3) | 203.5 (74) | .48 | ||||
|
|
|
Δ | –48.0 (69.3) | –56.7 (84.2) | .6 | ||||
|
|
Albumin (g/dL), mean (SD) |
|
|||||||
|
|
|
Pre-RT | 4.4 (0.3) | 4.4 (0.3) | .19 | ||||
|
|
|
Post-RT | 3.8 (0.5) | 4.0 (0.4) | .07 | ||||
|
|
|
Δ | –0.6 (0.4) | –0.5 (0.4) | .34 | ||||
|
|
NLRi, >mean (SD) |
|
|||||||
|
|
|
Pre-RT | 2.4 (1.0) | 2.5 (1) | .77 | ||||
|
|
|
Post-RT | 2.8 (3.7) | 3.1 (4.7) | .75 | ||||
|
|
|
Δ | 0.4 (3.9) | 0.6 (5.1) | .82 | ||||
|
|
PLRj, mean (SD) |
|
|||||||
|
|
|
Pre-RT | 125.3 ( 41.8) | 149.8 (54.1) | .02 | ||||
|
|
|
Post-RT | 209.4 (159.6) | 212.1 (160.8) | .94 | ||||
|
|
|
Δ | 84.1 (157.6) | 62.4 (173.4) | .55 | ||||
|
|
PNIk, mean (SD) |
|
|||||||
|
|
|
Pre-RT | 54.6 (4.2) | 54 (4.2) | .54 | ||||
|
|
|
Post-RT | 44.8 (5.7) | 47.3 (7.7) | .09 | ||||
|
|
|
Δ | –9.8 (6) | –6.7 (7.5) | .04 | ||||
aPatients who received surgery.
bcT: clinical tumor stage.
ccN: clinical nodal stage.
dRT: radiotherapy.
eSMI: skeletal muscle index.
fWBC: white blood cells.
gANC: absolute neutrophil count.
hALC: absolute lymphocyte count.
iNLR: neutrophil-to-lymphocyte ratio.
jPLR: platelet-to-lymphocyte ratio.
kPNI: prognostic nutritional index.